Tfiìô˜ 69 • T‡¯Ô˜ 2 a Ú›ÏÈÔ˜ – IÔ‡ÓÈÔ˜ 2003

Tfiìô˜ 69 • T‡¯Ô˜ 2 a Ú›ÏÈÔ˜ – IÔ‡ÓÈÔ˜ 2003

EÏÏËÓÈÎË I·ÙÚÈÎË TfiÌÔ˜ 69 • T‡¯Ô˜ 2 AÚ›ÏÈÔ˜ – IÔ‡ÓÈÔ˜ 2003 ¶ÂÚȯfiÌÂÓ· ∂ÓËÌÂÚˆÙÈο 93 H ÏÂÈÙÔ˘ÚÁ›· ÙÔ˘ ÊÏÔÈÔ‡ ÙˆÓ ÂÈÓÂÊÚȉ›ˆÓ ÛÙÔ Û‡Ó‰ÚÔÌÔ ¿ÚıÚ· ÙˆÓ ÔÏ˘Î˘ÛÙÈÎÒÓ ˆÔıËÎÒÓ A.H. KÔ‡ÚÙ˘, ¢.K. ¶·Ó›‰Ë˜ 101 YÂÚ·Û‚ÂÛÙÈ·ÈÌ›·: ¢È·ÁÓˆÛÙÈ΋ ÚÔÛ¤ÁÁÈÛË º. °ÎÈÚÙÔ‚›Ù˘, A. X·Ù˙ËÙfiÏÈÔ˜ 113 Yԉԯ›˜ ÙÔ˘ ÁÏÔ˘Ù·ÌÈÎÔ‡ ÔͤԘ ÛÙÔ ÎÂÓÙÚÈÎfi Ó¢ÚÈÎfi Û‡ÛÙËÌ· N. °ÎÔ˘ÁÎÔ˘ÏÈ¿˜, M. AÏÌ¿ÓË 132 O ¯˘Ìfi˜ ÙÔ˘ Vaccinium oxycoccos L. Î·È Ô ÚfiÏÔ˜ ÙÔ˘ ÛÙȘ Ô˘ÚÔÏÔÈÌÒÍÂȘ Î·È ¿ÏϘ ·ı‹ÛÂȘ ÙÔ˘ Ô˘ÚÔÔÈÔÁÂÓÓËÙÈÎÔ‡ Û˘ÛÙ‹Ì·ÙÔ˜ ∞. ∞ÔÛÙÔÏ›‰Ë˜, π. ÃÚ˘ÛÔÁÔÓ›‰Ë˜ ∂Ú¢ÓËÙÈΤ˜ 138 ∂ÈÔÏ·ÛÌfi˜ Ù˘ ¯ÚfiÓÈ·˜ ·ÔÊÚ·ÎÙÈ΋˜ Ó¢ÌÔÓÔ¿ıÂÈ·˜ ÂÚÁ·Û›Â˜ Î·È Ù˘ ÚÈÓ›Ùȉ·˜ ÛÙË µ. ∂ÏÏ¿‰· §. ™È¯ÏÂÙ›‰Ë˜, π. ∆ÛÈfiÙÛÈÔ˜, ¢. ÃψÚfi˜, ∞. °·‚ÚÈËÏ›‰Ë˜, ∂. ¢·ÛηÏÔÔ‡ÏÔ˘, £. ∫ˆÓÛÙ·ÓÙÈÓ›‰Ë˜ 148 ªÂÙ·‚ÔϤ˜ ÙˆÓ ÂȤ‰ˆÓ Ù˘ ‚-ÂÓ‰ÔÚÊ›Ó˘ Û ۯ¤ÛË Ì ÙËÓ Ô˘‰¤ÙÂÚË ÂÓ‰ÔÂÙȉ¿ÛË Î·È ÙÔ ÌÂÙ·ÙÚÂÙÈÎfi ¤Ó˙˘ÌÔ Ù˘ ·ÁÁÂÈÔÙ·Û›Ó˘ ÌÂÙ¿ ¿ÛÎËÛË ·ÓÙÔ¯‹˜ ‰È¿ÚÎÂÈ·˜ ÙÂÛÛ¿ÚˆÓ ÌËÓÒÓ ∏. ∫·ÏÏ›ÛÙÚ·ÙÔ˜, µ. ∫·ÏʷοÎÔ˘, ¶. µÂ˙˘Ú¿ÎË, ƒ. §È¿ÛÎÔ, ∞. ∂˘·ÁÁ¤ÏÔ˘ 154 ¢ÈÂÚ‡ÓËÛË ÙˆÓ ÔͤˆÓ ÛÙÂÊ·ÓÈ·›ˆÓ ÈÛ¯·ÈÌÈÎÒÓ ÂÂÈÛÔ‰›ˆÓ Û ‰È·‚ËÙÈÎÔ‡˜ ·ÛıÂÓ›˜ ∞. µ‹Ù·˜ ∂ӉȷʤÚÔ˘Û˜ 160 ∏·Ù›Ùȉ· ·fi ΢ÙÙ·ÚÔÌÂÁ·ÏÔ˚fi Û ÌË ·ÓÔÛÔηٷÛÙ·Ï̤ÓÔ ÂÓ‹ÏÈη ÂÚÈÙÒÛÂȘ ¢. °ÎÈÛ¿Î˘, π. ª·Ï¿ÓÔ˜, ∫. ¶·Û¯·Ï›‰Ë˜, ∞. ∫·Ú·ÁÈ¿ÓÓ˘, µ. ¶ÂÚËÊ¿Ó˘, º. ÷ÚÛÔ‡Ï˘ 163 ¡fiÛÔ˜ Kikuchi-Fujimoto: Ì›· Û¿ÓÈ· ·ÈÙ›· ÏÂÌÊ·‰ÂÓÔ¿ıÂÈ·˜ ¶. NÈÎÔÏ·˝‰Ë˜, A. ™ÔÊfi˜, B. K·ÏÔ‡ÙÛË, A. TÛÒÓ·, ¶. KÔÏÏ¿Ú·˜, ™. MÂÙ·ÏÏ›‰Ë˜, E. KÔ˘ÌÂÓÙ¿ÎË, A¯. TÔ˘ÚηÓÙÒÓ˘ 167 A˘ÙfiÌ·ÙË Ú‹ÍË ÂÈıËÏȷ΋˜ ·ÛÙ˘ ÛÏËÓfi˜ Û ¿ÙÔÌÔ ÙÚ›Ù˘ ËÏÈΛ·˜ X. ™˘Ú›‰Ë˜, A. NÙ›Ó·˜, °. ™Ê˘ÚfiÂÚ·˜, A. BÚ¿ÓÙ˙·˜, ™. AÏ MÔÁÚ·Ì›, £. °ÂÚ·ÛÈÌ›‰Ë˜ BÈ‚ÏÈÔ·ÚÔ˘Û›·ÛË 170 Helliniki Iatriki Volume 69 • No 2 April – June 2003 Contents Brief reviews 93 Adrenocortical function in polycystic ovary syndrome Kourtis AI, Panidis DK. 101 Hypercalcemia: Diagnostic process Girtovitis F, Chatzitolios AI. 113 Glutamate receptors in the CNS Gougoulias N, Albani M. 132 Cranberry juice: its role in the prevention and treatment of infections and other diseases of the urinary tract Apostolidis A, Chrissogonidis I. Investigative 138 The prevalence of chronic obstructive pulmonary disease papers and rhinitis in Northern Greece Sihletidis L, Tsiotsios I, Chloros D, Gavriilidis A, Daskalopulou E, Konstantinidis Th. 148 Alterations in serum ß-endorphin levels, in relation to neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) after four months endurance exercise Kallistratos E, Kalfakakou V, Vezyraki P, Liasko R, Evangelou A. 154 Coronary artery disease in patients with diabetes mellitus II Vitas A. Case reports 160 Hepatitis from cytomegalovirus (CMV) in an immunocompetent patient Gkisakis D, Balanos I, Paschalidis K, Karayiannis A, Perifanis B, Harsoulis F. 163 Kikuchi-Fujimoto disease: a rase cause of lymphadenitis Nikolaidis P. Sofos A, Kaloutsi V, Tsona A, Kollaras P, Metallidis S, Koumentaki E, Tourkantonis Ach. 167 Spontaneous rupture of an epithelial cyst of the spleen in an elderly Spiridis Ch, Dinas A, Sfireoras G, Vrantzas A, Al Mogrambi S, Gerasimidis Th. Book review 170 ∂ÏÏËÓÈ΋ π·ÙÚÈ΋ 2003, 69, 2: 93- 100 ∏ ÏÂÈÙÔ˘ÚÁ›· ÙÔ˘ ÊÏÔÈÔ‡ ÙˆÓ ÂÈÓÂÊÚȉ›ˆÓ ÛÙÔ Û‡Ó‰ÚÔÌÔ ÙˆÓ ÔÏ˘Î˘ÛÙÈÎÒÓ ˆÔıËÎÒÓ AÓ¿ÚÁ˘ÚÔ˜ H. KÔ‡ÚÙ˘, ¢ËÌ‹ÙÚÈÔ˜ K. ¶·Ó›‰Ë˜ ∂ÚÁ·ÛÙ‹ÚÈÔ ∂Ó‰ÔÎÚÈÓÔÏÔÁ›·˜ Î·È ∞ÓıÚÒÈÓ˘ ∞Ó··Ú·ÁˆÁ‹˜, µã ª·È¢ÙÈ΋ Î·È °˘Ó·ÈÎÔÏÔÁÈ΋ ∫ÏÈÓÈ΋, TÌ‹Ì· I·ÙÚÈ΋˜ ∞.¶.£., £ÂÛÛ·ÏÔÓ›ÎË ¶ÂÚ›ÏË„Ë. ∂›Ó·È ÁÓˆÛÙfi fiÙÈ ÙÔ 50-60% ÙˆÓ Á˘Ó·È- ÛÂÛËÌ·Ṳ̂ÓË ·‰ÚÂÓ·Ú¯‹ ÚÔÙ¿ıËÎÂ, ·Ú¯Èο, ˆ˜ ÎÒÓ Ì ÙÔ Û‡Ó‰ÚÔÌÔ ÙˆÓ ÔÏ˘Î˘ÛÙÈÎÒÓ ˆÔıËÎÒÓ ·ÈÙ›· Ù˘ ˘ÂÚ‚ÔÏÈ΋˜ ·Ú·ÁˆÁ‹˜ ·Ó‰ÚÔÁfiÓˆÓ ·- (PCOS) ÂÌÊ·Ó›˙ÂÈ ·‡ÍËÛË ÙˆÓ ÂȤ‰ˆÓ ÙˆÓ ÂÈ- fi Ù· ÂÈÓÂÊÚ›‰È· ÛÙÔ PCOS. ∏ ¿Ô„Ë Ô˘ Á›ÓÂÙ·È ÓÂÊÚȉȷÎÒÓ ·Ó‰ÚÔÁfiÓˆÓ. OÚÈṲ̂Ó˜ ÂÚÈÙÒÛÂȘ ÂÚÈÛÛfiÙÂÚÔ ‰ÂÎÙ‹ Û‹ÌÂÚ· Â›Ó·È Ë ·ÚÚÂÓÔÔÈËÙÈ΋ ÏÂÈÙÔ˘ÚÁÈ΋˜ ÂÈÓÂÊÚȉȷ΋˜ ˘ÂÚ·Ó‰ÚÔÁÔÓ·ÈÌ›·˜, Ú‡ıÌÈÛË ÙÔ˘ ÂÓ˙‡ÌÔ˘ ΢Ùfi¯ÚˆÌ· P450c17·. ∏ ·È- ı· ÌÔÚÔ‡Û·Ó, ·Ó·ÌÊÈÛ‚‹ÙËÙ·, Ó· ·Ô‰ÔıÔ‡Ó Û ٛ·, ¿ÓÙˆ˜, Ù˘ ÚˆÙÔ·ıÔ‡˜ ÏÂÈÙÔ˘ÚÁÈ΋˜ ÂÈ- ÔÔÈ·‰‹ÔÙ ηϿ ÙÂÎÌËÚȈ̤ÓË ·ıÔÊ˘ÛÈÔÏÔÁÈ- ÓÂÊÚȉȷ΋˜ ˘ÂÚ·Ó‰ÚÔÁÔÓ·ÈÌ›·˜ ÛÙÔ PCOS ·Ô- ΋ ÔÓÙfiÙËÙ·, fiˆ˜ Ë ÌË ÎÏ·ÛÈ΋ ‹ Ë fi„ÈÌ˘ ¤Ó·Ú- ÙÂÏ› ‰›Ô ·ÓÙÈÎÚÔ˘fiÌÂÓˆÓ ·fi„ˆÓ. ͢ Û˘ÁÁÂÓ‹˜ ˘ÂÚÏ·Û›· ÙˆÓ ÂÈÓÂÊÚȉ›ˆÓ. ∏ ÂÎ- EÏÏËÓ I·ÙÚ 2003, 69: 93 - 100. 1. ∂π™∞°ø°∏ ‰Ú¿ÛË Ù˘ ACTH ÛÙË ÛÙËÏȉˆÙ‹ ˙ÒÓË ‹ ÙË ‰Ú¿ÛË ∏ ‰Â¸‰ÚoÂÈ·Ó‰ÚoÛÙÂÚfiÓË (DHEA) Î·È Ë Úo- Ù˘ ·ÁÁÂÈoÙÂÓÛ›Ó˘ ππ ÛÙË ÛÂÈÚoÂȉ‹ ˙ÒÓË. ∆¤- oÚÌfiÓË Ù˘, Ë ıÂÈ˝Î‹ ‰Â¸‰ÚoÂÈ·Ó‰ÚoÛÙÂÚfiÓË ÙoÈo˜, fï˜, ·Ú¿ÁoÓÙ·˜ ‰ÂÓ ¤¯ÂÈ ‚ÚÂı›, ·Ú¿ ÙȘ (DHEA-S), Â›Ó·È ÛÙÂÚoÂȉ‹ Ì 19 ¿ÙoÌ· ¿Óıڷη ÂÎÙÂٷ̤Ó˜ ¤Ú¢Ó˜ ÛÙoÓ Ùo̤· ·˘Ùfi. Œ¯ÂÈ, ¿- Î·È Ì ·ÛıÂÓ›˜ ·Ó‰ÚoÁoÓÈΤ˜ ‰Ú¿ÛÂȘ. ∂ÎÎÚ›- ÓÙˆ˜, ÙÂÎÌËÚȈı› fiÙÈ ‚Ú·¯˘¯ÚfiÓȘ ÂÎÙÚo¤˜ Ù˘ ÓoÓÙ·È Û¯Â‰fiÓ ·oÎÏÂÈÛÙÈο ·fi ÙË ‰ÈÎÙ˘ˆÙ‹ ˙Ò- Û‡ÓıÂÛ˘ ÎoÚÙÈ˙fiÏ˘ Î·È ·Ó‰ÚoÁfiÓˆÓ, o˘ ÂÎÎÚ›- ÓË Ùo˘ ÊÏoÈo‡ ÙˆÓ ÂÈÓÂÊÚȉ›ˆÓ. ∆· ·ÙÙ·Ú· Ù˘ ÓoÓÙ·È ·fi Ù· ÂÈÓÂÊÚ›‰È·, ÌoÚ› Ó· oÊ›ÏoÓÙ·È ‰ÈÎÙ˘ˆÙ‹˜ ˙ÒÓ˘ ·Ú¿Áo˘Ó ΢ڛˆ˜ DHEA Î·È Û ˘ÂÚÈÓÛo˘ÏÈÓ·ÈÌ›·, Û ۇӉÚoÌo oÏ˘Î˘ÛÙÈÎÒÓ DHEA-S1 ‡ÛÙÂÚ· ·fi ‰È¤ÁÂÚÛË Ì ÊÏoÈoÂÈÓÂ- ˆoıËÎÒÓ, Û o͇ Î·È ¯ÚfiÓÈo stress, Û Ó¢ÚoÁÂÓ‹ ÊÚȉÈoÙÚfio oÚÌfiÓË (ACTH), ·Êo‡ ‰ÂÓ ‰È·ı¤- ·ÓoÚÂÍ›·, Û ˘„ËÏ¿ ›‰· oÈÛÙÚoÁfiÓˆÓ Î·È Û Ùo˘Ó Ùo ¤Ó˙˘Ìo o˘ ÌÂÙ·ÙÚ¤ÂÈ ÙËÓ DHEA Û ·Ó- ÂÁ΢ÌoÛ‡ÓË. ªoÏoÓfiÙÈ oÈ Ì˯·ÓÈÛÌo› o˘ Úo- ηÏo‡Ó ·˘Ù¤˜ ÙȘ ‚Ú·¯˘¯ÚfiÓȘ ÂÎÙÚo¤˜ ‰ÂÓ ¤¯o˘Ó ‰ÚoÛÙÂÓ‰ÈfiÓË (¢4∞) (EÈÎ. 1). ∞ÓÙ›ıÂÙ·, Ù· ·ÙÙ·- Ú· Ù˘ ÛÙËÏȉˆÙ‹˜ ˙ÒÓ˘ Ùo˘ ÊÏoÈo‡ ÙˆÓ ÂÈÓÂ- Ï‹Úˆ˜ ‰È¢ÎÚÈÓÈÛı›, Â›Ó·È ÂӉ¯fiÌÂÓo Ë ÈÓÛo˘Ï›- ÊÚȉ›ˆÓ ·Ú¿Áo˘Ó ΢ڛˆ˜ ÎoÚÙÈ˙fiÏË Î·È ÌÈÎÚ¿ ÓË Î·È Ù· oÈÛÙÚoÁfiÓ· Ó· ÂϤÁ¯o˘Ó ÙËÓ ¤ÎÊÚ·ÛË Î·È oÛ¿ ÂÈÓÂÊÚȉȷÎÒÓ ·Ó‰ÚoÁfiÓˆÓ Î·È Ù· ·ÙÙ·- ÙË ÏÂÈÙo˘ÚÁ›· ÙˆÓ ÛÙÂÚoÂȉoÁÂÓÂÙÈÎÒÓ ÂÓ˙‡ÌˆÓ3. Ú· Ù˘ ÛÂÈÚoÂȉo‡˜ ˙ÒÓ˘ ·Ú¿Áo˘Ó ΢ڛˆ˜ ·Ï- ∆· ›‰· Ù˘ DHEA-S Ùo˘ oÚo‡, Ë oo›· ‰oÛÙÂÚfiÓË (EÈÎ. 1)2,3. ıˆÚÂ›Ù·È ÛÙ·ıÂÚfi˜ ‰Â›ÎÙ˘ Ù˘ ·Ú·ÁˆÁ‹˜ ÂÈ- O ¤ÏÂÁ¯o˜ Ù˘ ¤ÎÎÚÈÛ˘ ÙˆÓ ·Ó‰ÚoÁfiÓˆÓ ·fi ÓÂÊÚȉȷÎÒÓ ·Ó‰ÚoÁfiÓˆÓ, ÂÌÊ·Ó›˙o˘Ó ¤ÓÙoÓ˜ Ùo ÊÏoÈfi ÙˆÓ ÂÈÓÂÊÚȉ›ˆÓ ·Ú·Ì¤ÓÂÈ, ·ÎfiÌË Î·È ÌÂÙ·‚oϤ˜ ηٿ ÙËÓ ‰È¿ÚÎÂÈ· Ù˘ ˙ˆ‹˜ Ùo˘ ·Ùfi- Û‹ÌÂÚ·, ¤Ó· ·›ÓÈÁÌ·. ÀoÛÙËÚ›¯ıËΠfiÙÈ Î¿oÈo˜ Ìo˘. ™Ùo ¤Ì‚Ú˘o, Ù· ›‰· Ù˘ DHEA-S Â›Ó·È oÏ˘ÂÙȉÈÎfi˜ ·Ú¿ÁoÓÙ·˜ ·fi ÙËÓ ˘fiÊ˘ÛË ÂÍ·ÈÚÂÙÈο ˘„ËÏ¿. ™ÙË Ê¿ÛË ·˘Ù‹ Ë oÓoÌ·˙fiÌÂÓË ‰ÈÂÁ›ÚÂÈ ÂȉÈο ÙË ‰ÈÎÙ˘ˆÙ‹ ˙ÒÓË, ·Ó¿ÏoÁ· Ì ÙË ÂÌ‚Ú˘˚΋ ˙ÒÓË Ùo˘ ÊÏoÈo‡ ÙˆÓ ÂÈÓÂÊÚȉ›ˆÓ Â›Ó·È 94 A.H. KO⁄ƒ∆∏™, ¢.K. ¶∞¡π¢∏™ Xοληστερόλη AΛATO ΓΛYKO OPMONEΣ StAR KOPTIKOEI∆H KOPTIKOEI∆H ΦYΛOY SCC πρωτεΐνη Θειϊκή δεϋδροεπιανδροστερόνη 17·- 17,20- ˘‰ÚÔÍ˘Ï¿ÛË 17-OH Ï˘¿ÛË ∆εϋδρο- 17‚-HSD Πρεγνενολόνη πρεγνενολόνη επιανδροστερόνη Aνδροστενεδιόλη 3‚-HSD 3‚-HSD 3‚-HSD 3‚-HSD 17·- 17,20- FSH/LH ˘‰ÚÔÍ˘Ï¿ÛË 17-OH Ï˘¿ÛË 17‚-HSD Προγεστερόνη Aνδροστενδιόνη Tεστοστερόνη προγεστερόνη Aڈ̷ٿÛË Aڈ̷ٿÛË ACTH 21- 21-˘‰ÚÔÍ˘Ï¿ÛË ˘‰ÚÔÍ˘Ï¿ÛË 17‚-HSD ∆εοξυκορτικοστερόνη 11-δεοξυκορτιζόλη Oιστρόνη Oιστραδιόλη 11‚-˘‰ÚÔÍ˘Ï¿ÛË 11‚-˘‰ÚÔÍ˘Ï¿ÛË Kορτικοστερόνη Kορτιζόλη 18-˘‰ÚÔÍ˘Ï¿ÛË 18-OH κορτικοστερόνη 18-OH ‰Â¸‰ÚÔÁÂÓ¿ÛË Aλδοστερόνη ∂ÈÎ. 1. BÈÔÛ˘ÓıÂÙÈΤ˜ Ô‰Ô› ·Ú·ÁˆÁ‹˜ ÛÙÂÚÔÂȉÒÓ ÔÚÌÔÓÒÓ ÛÙÔ ÊÏÔÈfi ÙˆÓ ÂÈÓÂÊÚȉ›ˆÓ. ˘ÂÚ‚oÏÈο ·Ó·Ù˘Á̤ÓË. ⁄ÛÙÂÚ· ·fi ÙË Á¤ÓÓË- ⁄ÛÙÂÚ· ·fi ÙËÓ ËÏÈΛ· ÙˆÓ 25 ÂÙÒÓ, oÈ Û˘Á- ÛË, ÂÓÙo‡ÙoȘ, Ë ÂÌ‚Ú˘˚΋ ˙ÒÓË ·ÙÚoÊ› Ù·¯‡Ù·Ù· ÎÂÓÙÚÒÛÂȘ Ù˘ DHEA Î·È Ù˘ DHEA-S ÂÏ·ÙÙÒ- Î·È Ë DHEA-S Ùo˘ oÚo‡ Â›Ó·È Û¯Â‰fiÓ ÌË ·ÓȯÓ‡- ÓoÓÙ·È Úoo‰Â˘ÙÈο. ŒÙÛÈ, ÛÙËÓ ËÏÈΛ· ÙˆÓ 70 Â- ÛÈÌË. ™Ù· ¯·ÌËÏ¿ ·˘Ù¿ ›‰· ·Ú·Ì¤ÓÂÈ Ë ÙÒÓ oÈ ÙÈ̤˜ ÙˆÓ oÚÌoÓÒÓ ·˘ÙÒÓ Êı¿Óo˘Ó ÛÙo 10- DHEA-S Ùo˘ oÚo‡ Û fiÏË ÙË ‰È¿ÚÎÂÈ· Ù˘ ·È‰È- 20% ÙˆÓ ÎoÚ˘Ê·›ˆÓ Ùo˘˜ ÂȤ‰ˆÓ5. ∏ ÂÚ›o‰o˜ ΋˜ ËÏÈΛ·˜, ̤¯ÚÈ ÙËÓ ·‰ÚÂÓ·Ú¯‹1. ·˘Ù‹ Ù˘ ˙ˆ‹˜, ÁÓˆÛÙ‹ ˆ˜ ·‰ÚÂÓfi·˘ÛË, Û¯ÂÙ›˙Â- ∞‰ÚÂÓ·Ú¯‹ oÓoÌ¿˙ÂÙ·È Ë ¤Ó·ÚÍË Ù˘ ‚ÈoÛ‡Ó- Ù·È Ì ÙË «Á‹Ú·ÓÛË» Ù˘ ‰ÈÎÙ˘ˆÙ‹˜ ˙ÒÓ˘ ÙˆÓ ÂÈ- ıÂÛ˘ ÙˆÓ ÂÈÓÂÊÚȉȷÎÒÓ ·Ó‰ÚoÁfiÓˆÓ, DHEA, ÓÂÊÚȉ›ˆÓ. O Ì·ÎÚo¯ÚfiÓÈo˜, ÏoÈfiÓ, ¤ÏÂÁ¯o˜ ÙˆÓ DHEA-S Î·È ¢4∞, o˘ ·Ú·ÙËÚÂ›Ù·È ·Ó¿ÌÂÛ· ÛÙo ÂȤ‰ˆÓ ÙˆÓ ÂÈÓÂÊÚȉȷÎÒÓ ·Ó‰ÚoÁfiÓˆÓ Ú˘ıÌ›- ¤‚‰oÌo Î·È ÛÙo ‰¤Î·Ùo ¤Ùo˜ Ù˘ ËÏÈΛ·˜. O ÊÏoÈfi˜ ˙ÂÙ·È ·fi ÙȘ ÌÂÙ·‚oϤ˜ Ù˘ ‰ÈÎÙ˘ˆÙ‹˜ ˙ÒÓ˘2. ÙˆÓ ÂÈÓÂÊÚȉ›ˆÓ ·Ú¿ÁÂÈ ÛÙ·ıÂÚ¤˜ oÛfiÙËÙ˜ ∏ ·‰ÚÂÓfi·˘ÛË ÌoÚ› Ó· ·oÙÂÏ› ‚ÈoÏoÁÈ- ÎoÚÙÈ˙fiÏ˘ Û ۯ¤ÛË Ì ÙËÓ ÂÈÊ¿ÓÂÈ· Ùo˘ ÛÒ- Îfi ‰Â›ÎÙË Á‹Ú·ÓÛ˘, ÌoÚ›, fï˜, Ó· ·oÙÂÏ› Ì·Ùo˜ Û fiÏË ÙË ‰È¿ÚÎÂÈ· Ù˘ ˙ˆ‹˜.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    79 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us